Bioelectronic medicine & neuromodulation

Bioelectronic medicine treats disease by electrically stimulating a specific nerve pathway rather than with a drug. SetPoint Medical received FDA approval in July 2025 for its neuroimmune modulation therapy for rheumatoid arthritis, the first clinically proven neuromodulation treatment for the condition, and its RESET-RA study was published in Nature Medicine in January 2026 demonstrating durable efficacy and safety; a May 2026 cost-effectiveness study further confirmed the therapy can reduce total cost of care and improve quality of life. Nevro Corp’s HFX iQ spinal cord stimulation system, which integrates AI-driven personalization with its 10 kHz therapy, received CE Mark certification in Europe in November 2024 and holds an FDA-specific indication for non-surgical back pain. Inspire Medical Systems continued to expand evidence for its next-generation hypoglossal nerve stimulation therapy for obstructive sleep apnea, presenting final ADHERE registry results covering more than 5,000 patients and the OSPREY randomized trial at SLEEP 2026 in June. Galvani Bioelectronics’ splenic neuromodulation therapy for rheumatoid arthritis received FDA approval to progress to the randomized, controlled stage of clinical feasibility testing. Onward Medical reported EUR 2 million in first-quarter 2026 revenue, achieved first-in-human use of its ARC-IM lumbar lead designed to restore standing, stepping and lower-limb mobility after spinal cord injury, and enrolled its first patient in the Empower BP global pivotal study addressing post-injury blood pressure instability. In China, PINS Medical’s implantable deep brain neurostimulation system received NMPA market approval, and the company separately received an innovation green-channel designation for a deep brain stimulator targeting treatment-resistant obsessive-compulsive disorder.

The key directions of bioelectronic medicine & neuromodulation are:

1. Neuroimmune modulation for autoimmune disease (Neuroimmune Modulation): vagus and splenic nerve stimulation that suppresses inflammation as an alternative to immunosuppressive drugs, validated in rheumatoid arthritis — SetPoint Medical’s FDA-approved cervical VNS therapy and Galvani Bioelectronics’ splenic neuromodulation platform.
2. AI-personalized spinal cord stimulation for chronic pain (AI Spinal Cord Stimulation): closed-loop, AI-tuned stimulation for chronic pain including a dedicated non-surgical back pain indication — Nevro Corp’s HFX iQ/HFX AdaptivAI.
3. Hypoglossal nerve stimulation for sleep apnea (Hypoglossal Nerve Stimulation): implantable nerve stimulators that prevent airway collapse during sleep, backed by large-scale registry and randomized-trial evidence — Inspire Medical Systems.
4. Implantable neuromodulation for paralysis and neurological disease (Implantable Neuromodulation for Movement): spinal cord and deep brain stimulation systems restoring movement after spinal cord injury or treating neurological/psychiatric disease — Onward Medical’s ARC-IM/ARC-EX platform and PINS Medical’s deep brain stimulation systems.

Sectoral value chain#

[nerve target/stimulation waveform design] ──> [preclinical/clinical validation] ──> [regulatory clearance (FDA/MDR/NMPA)]
                                                    │
                                       (implantation/device programming)
                                                    │
                                                    ▼
[registry/outcomes-driven label expansion] <─── [clinical outcome data generation] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Neuroimmune modulation (Neuroimmune Modulation): electrical stimulation of the vagus or splenic nerve to suppress inflammatory cytokine release, offering a drug-free mechanism for autoimmune disease control.
• AI-personalized stimulation tuning (AI Spinal Cord Stimulation): cloud-connected, AI-driven algorithms that adjust stimulation parameters to individual patient response over time.
• Registry-scale evidence generation (Hypoglossal Nerve Stimulation): large longitudinal patient registries (thousands of patients) and randomized trials used to expand and defend a neurostimulation therapy’s indication.

The stack applies targeted electrical stimulation to a specific nerve pathway to treat disease mechanistically, as an alternative or complement to pharmacological treatment.

1. Neuroimmune modulation therapy (Neuroimmune Modulation):
   • SetPoint Medical’s FDA-approved cervical vagus nerve stimulator suppresses inflammatory cytokine release in rheumatoid arthritis, with Galvani Bioelectronics developing a splenic-nerve alternative now advancing to randomized controlled testing.
2. AI-personalized spinal cord stimulation (AI Spinal Cord Stimulation):
   • Nevro Corp’s HFX iQ combines 10 kHz high-frequency therapy with AI-driven, cloud-connected personalization (HFX AdaptivAI) and holds a dedicated FDA indication for non-surgical back pain.
3. Hypoglossal nerve stimulation (Hypoglossal Nerve Stimulation):
   • Inspire Medical Systems’ next-generation Inspire V system uses respiratory-sensing hypoglossal nerve stimulation for obstructive sleep apnea, backed by the 5,000-patient ADHERE registry and the OSPREY randomized trial.
4. Implantable neuromodulation for movement restoration (Implantable Neuromodulation for Movement):
   • Onward Medical’s ARC-IM implantable and ARC-EX non-invasive spinal cord stimulation systems restore standing, stepping and lower-limb mobility after spinal cord injury, while PINS Medical’s deep brain stimulation systems treat movement and, via its OCD-focused device, psychiatric indications in China.